Literature DB >> 2958291

Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease.

T Norman1, E Chiu, R H James, M S Gregory.   

Abstract

The pharmacokinetic properties of a single oral dose of 100 mg of tiapride were studied in six patients with Huntington's disease. The results for five patients were consistent with a two compartment open model. Peak plasma concentrations were observed within 2 h following drug administration with a mean value of 0.92 micrograms/ml being recorded. The drug was rapidly eliminated as unmetabolised tiapride in the urine, 51% of the dose was recovered in 24 h. The plasma elimination half-life was 5.3 h and the average apparent plasma clearance was 16.6 l/h.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2958291     DOI： 10.1007/bf02455992

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  11 in total

1.  A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs.

Authors:  P Jenner; P N Elliott; A Clow; C Reavill; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1978-01       Impact factor: 3.765

2.  Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease.

Authors:  R A Roos; E J de Haas; O J Buruma; F A de Wolff
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Substituted benzamides as cerebral dopamine antagonists in rodents.

Authors:  P N Elliott; P Jenner; G Huizing; C D Marsden; R Miller
Journal:  Neuropharmacology       Date:  1977-05       Impact factor: 5.250

4.  Tiapride in Parkinson's disease.

Authors:  P Price; J D Parkes; C D Marsden
Journal:  Lancet       Date:  1978-11-18       Impact factor: 79.321

5.  Tiapride in levodopa-induced involuntary movements.

Authors:  B Mejer Nielsen
Journal:  Acta Neurol Scand       Date:  1983-06       Impact factor: 3.209

6.  Tiapride in the treatment of Huntington's chorea.

Authors:  R A Roos; O J Buruma; G W Bruyn; B Kemp; E A van der Velde
Journal:  Acta Neurol Scand       Date:  1982-01       Impact factor: 3.209

7.  Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms.

Authors:  E Rey; P d'Athis; M O Richard; D de Lauture; G Olive
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-02

8.  Tiapride in levodopa-induced involuntary movements.

Authors:  A J Lees; C M Lander; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-04       Impact factor: 10.154

9.  Tiapride in the treatment of tardive dyskinesia.

Authors:  O J Buruma; R A Roos; G W Bruyn; B Kemp; E A van der Velde
Journal:  Acta Neurol Scand       Date:  1982-01       Impact factor: 3.209

10.  Tiapride: effects on tardive dyskinesia and on prolactin plasma concentrations.

Authors:  W Greil; S Auberger; H Haag; E Rüther
Journal:  Neuropsychobiology       Date:  1985       Impact factor: 2.328
View more
  6 in total

1.  A new oral formulation of tiapride (drops): pharmacokinetic profile and therapeutic applications.

Authors:  M Canal; C R Desanti; J P Santoni
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 2.  Tiapride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in geriatric agitation.

Authors:  J W Steele; D Faulds; E M Sorkin
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 3.  Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.

Authors:  D H Peters; D Faulds
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

4.  Opposing effects of dopamine antagonism in a motor sequence task-tiapride increases cortical excitability and impairs motor learning.

Authors:  Silke Lissek; Guido S Vallana; Lara Schlaffke; Melanie Lenz; Hubert R Dinse; Martin Tegenthoff
Journal:  Front Behav Neurosci       Date:  2014-06-19       Impact factor: 3.558

5.  The DA antagonist tiapride impairs context-related extinction learning in a novel context without affecting renewal.

Authors:  Silke Lissek; Benjamin Glaubitz; Oliver T Wolf; Martin Tegenthoff
Journal:  Front Behav Neurosci       Date:  2015-09-03       Impact factor: 3.558

6.  Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride.

Authors:  Stefanie Fekete; K Egberts; T Preissler; C Wewetzer; C Mehler-Wex; M Romanos; M Gerlach
Journal:  Eur J Clin Pharmacol       Date:  2020-09-28       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.